Skip to main content

CLLS

Stock
Health Care
Biotechnology

Performance overview

CLLS Price
Price Chart

Forward-looking statistics

Beta
2.23
Risk
84.77%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Company info

SectorHealth Care
IndustryBiotechnology
Employees249
Market cap$257.2M

Fundamentals

Enterprise value$78.8M
Revenue$54.7M
Revenue per employee
Profit margin-110.57%
Debt to equity82.81

Security info

ExchangeNASDAQ
Type of shareADR
Earnings per share (EPS)-$0.67
Dividend per share
Revenue per share$0.56
Avg trading volume (30 day)$146K
Avg trading volume (10 day)$143K
Put-call ratio

Macro factor sensitivity

Growth-4.8
Credit+11.4
Liquidity+0.4
Inflation-9.0
Commodities-2.1
Interest Rates-3.7

Valuation

Dividend yield0.00%
PEG Ratio-2.08
Price to sales2.98
P/E Ratio-2.08
Enterprise Value to Revenue1.44
Price to book0.98

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day
Ex. dividend day

News

Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS)

Cellectis (CLLS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Investment Research (July 10, 2024)
Cytovia, Cellectis Expand Collaboration On Gene-Edited Cancer Platform In China

Cytovia Therapeutics Inc and Cellectis SA (NASDAQ: CLLS) have expanded their collaboration of TALEN gene-edited iPSC-derived NK and CAR-NK cells. The expanded agreement will include a new CAR target and development in China by Cytovia's joint venture entity, CytoLynx Therapeutics.

Benzinga (November 19, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free